Determine the association of marijuana use with serious psychological distress (SPD) among adults aged 18 years or older using a large, nationally representative sample of US households.
Design
Cross-sectional analysis.
Setting
Data from the National Survey on Drug Use and Health, 2021.
Subjects
47,247 respondents representing 253.7 million adults (age>18 years) in the US.
Measures
Marijuana use was categorized as (1) None, (2) within the past month, (3) within 1 year, and (4) more than a year ago from the interview time. SPD was measured with the Kessler-6 distress scale.
Analysis
Bivariable and multivariable logistic regression analyses accounting for complex survey designs were conducted.
Results
Among adults in the US, 50.9% never used marijuana, 13.7%, 6.0%, and 29.4% reported marijuana use in the past month, in the past year, and more than a year ago, respectively. Individuals using marijuana within the past month, within a year, and more than a year ago reported higher past month SPD (15.3%, 13.5%, and 6.8%, respectively) than never-users (4.9%). Adjusted logistic regression analysis revealed that marijuana use in the past month, past year (1-12 months), and over a year ago is associated with higher SPD (AOR [95% CI] = 2.06 [1.72, 2.45]; 1.82 [1.50, 2.21]; 1.53 [1.26, 1.87], respectively) compared to no marijuana use.
Conclusion
Adults who used marijuana more recently were more likely to report SPD.
SharmaPMurthyPBharathMMS. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7(4):149-156.
2.
ChoiNGMartiCNDiNittoDMChoiBY. Psychological distress, cannabis use frequency, and cannabis use disorder among US adults in 2020. J Psychoact Drugs. 2023;55(4):445-455. doi:10.1080/02791072.2022.2142708
3.
CreanRDCraneNAMasonBJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addiction Med. 2011;5(1):1-8. doi:10.1097/ADM.0b013e31820c23fa
4.
DoughertyDMMathiasCWDawesMA, et al.Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology. 2013;226(2):307-319. doi:10.1007/s00213-012-2908-5
5.
HowlettACBlumeLCDaltonGD. CB(1) cannabinoid receptors and their associated proteins. Curr Med Chem. 2010;17(14):1382-1393. doi:10.2174/092986710790980023
6.
PattonD. A history of United States cannabis law. J Law Health. 2020;34(1):1-29.
7.
PaculaRLSmartR. Medical marijuana and marijuana legalization. Annu Rev Clin Psychol. 2017;13:397-419. doi:10.1146/annurev-clinpsy-032816-045128
LynchMECampbellF. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72(5):735-744. doi:10.1111/j.1365-2125.2011.03970.x
11.
HillKP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474-2483. doi:10.1001/jama.2015.6199
12.
KoppelBSBrustJCMFifeT, et al.Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563. doi:10.1212/WNL.0000000000000363
13.
DeshpandeAMailis-GagnonAZoheiryNLakhaSF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Physician. 2015;61(8):e372-e381.
14.
NaftaliTBar-Lev SchleiderLDotanILanskyEPSklerovsky BenjaminovFKonikoffFM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11(10):1276-1280.e1. doi:10.1016/j.cgh.2013.04.034
15.
NaftaliTMechulamRMariiA, et al.Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Dig Dis Sci. 2017;62(6):1615-1620. doi:10.1007/s10620-017-4540-z
16.
PawasaratIMSchultzEMFrisbyJC, et al.The efficacy of medical marijuana in the treatment of cancer-related pain. J Palliat Med. 2020;23(6):809-816. doi:10.1089/jpm.2019.0374
17.
WhitingPFWolffRFDeshpandeS, et al.Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
18.
BergamaschiMMQueirozRHCChagasMHN, et al.Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038/npp.2011.6
19.
BlessingEMSteenkampMMManzanaresJMarmarCR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836. doi:10.1007/s13311-015-0387-1
20.
OberbarnscheidtTMillerNS. The impact of cannabidiol on psychiatric and medical conditions. J Clin Med Res. 2020;12(7):393-403. doi:10.14740/jocmr4159
21.
DevinskyOCrossJHLauxL, et al.Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
22.
SteenkampMMBlessingEMGalatzer-LevyIRHollahanLCAndersonWT. Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: a literature review. Depress Anxiety. 2017;34(3):207-216. doi:10.1002/da.22596
23.
BudneyAJRoffmanRStephensRSWalkerD. Marijuana dependence and its treatment. Addiction Sci Clin Pract. 2007;4(1):4-16. doi:10.1151/ascp07414
24.
PattonGCCoffeyCCarlinJBDegenhardtLLynskeyMHallW. Cannabis use and mental health in young people: cohort study. BMJ. 2002;325(7374):1195-1198. doi:10.1136/bmj.325.7374.1195
25.
RamaekersJGKauertGTheunissenELToennesSWMoellerMR. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol. 2009;23(3):266-277. doi:10.1177/0269881108092393
26.
TashkinDP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10(3):239-247. doi:10.1513/AnnalsATS.201212-127FR
27.
ThomasGKlonerRARezkallaS. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187-190. doi:10.1016/j.amjcard.2013.09.042
28.
MurrayRMQuigleyHQuattroneDEnglundADi FortiM. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatr. 2016;15(3):195-204. doi:10.1002/wps.20341
29.
SingleAAlcoladoGKeoughMTMotaN. Cannabis use and social anxiety disorder in emerging adulthood: results from a nationally representative sample. J Anxiety Disord. 2023;101:102808. doi:10.1016/j.janxdis.2023.102808Published online December 4.
30.
SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2021. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report
PR Newswire. US-cannabis Market Is to Grow by USD 46.90 Billion between 2022 - 2027 | Rising Millennial Population Drive Demand for the Market - Technavio. Yahoo Finance; 2023. Published November 9, 2023. https://finance.yahoo.com/news/us-cannabis-market-grow-usd-021500879.html. Accessed 17 January 2024.
33.
CuttlerCMischleyLKSextonM. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 2016;1(1):166-175. doi:10.1089/can.2016.0010
34.
JeffersAMGlantzSByersAKeyhaniS. Sociodemographic characteristics associated with and prevalence and frequency of cannabis use among adults in the US. JAMA Netw Open. 2021;4(11):e2136571. doi:10.1001/jamanetworkopen.2021.36571
35.
MontgomeryLDixonSManteyDS. Racial and ethnic differences in cannabis use and cannabis use disorder: implications for researchers. Curr Addict Rep. 2022;9(1):14-22. doi:10.1007/s40429-021-00404-5
36.
KesslerRCAndrewsGColpeLJ, et al.Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32(6):959-976. doi:10.1017/s0033291702006074
37.
WeissmanJPrattLMillerEParkerJ. Serious Psychological Distress Among Adults: United States, 2009–2013. National Center for Health Statistics. 2015; 2019. https://www.cdc.gov/nchs/products/databriefs/db203.htm. Accessed 1 May 2024.
CerdáMMauroCHamiltonA, et al.Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatr. 2020;77(2):165-171. doi:10.1001/jamapsychiatry.2019.3254
40.
AlhussainKMerayaAMSambamoorthiU. Serious psychological distress and emergency room use among adults with multimorbidity in the United States. Psychiatry J. 2017;2017:8565186. doi:10.1155/2017/8565186
41.
McGintyEEPresskreischerRHanHBarryCL. Psychological distress and loneliness reported by US adults in 2018 and April 2020. JAMA. 2020;324(1):93-94. doi:10.1001/jama.2020.9740
42.
OlfsonMWangSWallMMarcusSCBlancoC. Trends in serious psychological distress and outpatient mental health care of US adults. JAMA Psychiatr. 2019;76(2):152-161. doi:10.1001/jamapsychiatry.2018.3550
43.
WeinbergerAHPacekLRShefferCEBudneyAJLeeJGoodwinRD. Serious psychological distress and daily cannabis use, 2008 to 2016: potential implications for mental health?Drug Alcohol Depend. 2019;197:134-140. doi:10.1016/j.drugalcdep.2019.01.010
44.
LivneOShmulewitzDLev-RanSHasinDS. DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. adults. Drug Alcohol Depend. 2019;195:170-177. doi:10.1016/j.drugalcdep.2018.09.005
45.
National Academies of Sciences E, Division H and M, Practice B on PH and PH, Agenda C on the HE of MAER and R. Therapeutic effects of cannabis and cannabinoids. In: The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. National Academies Press (US); 2017. https://www.ncbi.nlm.nih.gov/books/NBK425767/. Accessed 5 December 2023.
46.
ShrivastavaAJohnstonMTsuangM. Cannabis use and cognitive dysfunction. Indian J Psychiatr. 2011;53(3):187-191. doi:10.4103/0019-5545.86796
47.
EvansDG. Marijuana legalization will cause many problems for Missouri law enforcement and schools. Mo Med. 2019;116(3):164-167.
48.
SchoelerTTheobaldDPingaultJB, et al.Continuity of cannabis use and violent offending over the life course. Psychol Med. 2016;46(8):1663-1677. doi:10.1017/S0033291715003001
49.
PearlsonGDStevensMCD’SouzaDC. Cannabis and driving. Front Psychiatr. 2021;12:689444. doi:10.3389/fpsyt.2021.689444
50.
WomackSRShawDSWeaverCMForbesEE. Bidirectional associations between cannabis use and depressive symptoms from adolescence through early adulthood among at-risk young men. J Stud Alcohol Drugs. 2016;77(2):287-297. doi:10.15288/jsad.2016.77.287
